Terminated, withdrawn and suspended trials

clinicaltrialsObservedShowing 501–550 of 709 studies, most recently updated first

NCT	Title	Phase	Status	First posted	Lead sponsor	Why stopped (as posted)	Category
NCT01484860	Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line…	Phase 2	terminated	Dec 2, 2011	University Health Network, Toronto	not stated	Not stated
NCT02748304	Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With…	N/A	terminated	Apr 22, 2016	Fudan University	The enrollment of this study was slow. With the approval of lenvatinib in HCC,many patients choose…	Enrollment / accrual
NCT02828124	A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer	Phase 1 / Phase 2	terminated	Jul 11, 2016	Bristol-Myers Squibb	Business objectives have changed	Sponsor / business decision
NCT02570529	Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally…	Phase 4	withdrawn	Oct 7, 2015	Yonsei University	Investigator decided to stop the study because it was difficult to proceed with the study.	Investigator
NCT03779100	Lenvatinib Plus PD-1 Antibody for Unresectable ICC	Phase 2	suspended	Dec 19, 2018	Shi Ming	Protocol modification	Other (stated, no rule matched)
NCT01600196	Resection vs. Best Supportive Care for Hepatocellular Carcinoma (HCC) With Portal Venous…	Phase 4	terminated	May 16, 2012	Sun Yat-sen University	not stated	Not stated
NCT02220088	The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a…	Phase 2 / Phase 3	terminated	Aug 19, 2014	Sun Yat-sen University	protocol violation	Other (stated, no rule matched)
NCT01855724	Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in…	Phase 2	terminated	May 16, 2013	Hellenic Cooperative Oncology Group	not stated	Not stated
NCT03035006	Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein…	Phase 1 / Phase 2	terminated	Jan 27, 2017	Taiwan Liposome Company	Current study design couldn't support futher development on this indication.	Other (stated, no rule matched)
NCT02787954	Prospective Tumor Response Evaluation(Liver)	—	terminated	Jun 1, 2016	The University of Texas Health Science Center, Houston	PI transferred to another institution and did not take this study with him.	Other (stated, no rule matched)
NCT02254681	Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC	Phase 2	terminated	Oct 2, 2014	Allina Health System	lack of funding	Funding
NCT02599909	Gut Microbiota in People With Hepatocellular Carcinoma (HCC)	—	withdrawn	Nov 9, 2015	National Cancer Institute (NCI)	not stated	Not stated
NCT02204124	Whipple Procedure: Standard of Care vs. Thunderbeat	N/A	terminated	Jul 30, 2014	Washington University School of Medicine	Principal Investigator and Study Sponsor decided to terminate the study early	Investigator
NCT02967523	Surefire Precision Infusion System Registry	—	terminated	Nov 18, 2016	Surefire Medical, Inc.	not stated	Not stated
NCT03345225	A Clinical Study of Precision TACE (P-TACE) With Surefire	N/A	withdrawn	Nov 17, 2017	University of Miami	Funding	Funding
NCT02650635	TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic,…	Phase 1	terminated	Jan 8, 2016	Mayo Clinic	permanently closed per sponsor's request	Other (stated, no rule matched)
NCT01425996	A Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced…	Phase 1 / Phase 2	terminated	Aug 30, 2011	Taiwan Liposome Company	not stated	Not stated
NCT01921751	High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and…	Phase 2	terminated	Aug 13, 2013	Radiation Therapy Oncology Group	Trial would not be completed in a reasonable timeframe per CTEP guidelines	Other (stated, no rule matched)
NCT02345460	Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study	Phase 2	terminated	Jan 26, 2015	Case Comprehensive Cancer Center	Competing studies	Other (stated, no rule matched)
NCT02057874	3-Tesla MRI Response to TACE in HCC (Liver Cancer)	N/A	terminated	Feb 7, 2014	Vanderbilt-Ingram Cancer Center	Funding unavailable	Funding
NCT00832637	Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers(Gem-ox)	Phase 2	terminated	Jan 30, 2009	New Mexico Cancer Research Alliance	Low accrual	Enrollment / accrual
NCT03168152	Randomized Trial Comparing Stereotactic Body Radiation Therapy to Microwave Ablation for…	N/A	withdrawn	May 30, 2017	University of Michigan Rogel Cancer Center	No patients were accrued to the trial	Enrollment / accrual
NCT02748161	DEB-TACE for Hepatocellular Carcinoma(QED)	N/A	terminated	Apr 22, 2016	Surefire Medical, Inc.	Low enrollment	Enrollment / accrual
NCT02702960	Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow…	Phase 2	withdrawn	Mar 9, 2016	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	This study was withdrawn due to lack of necessary resources from the liver transplant surgical…	Other (stated, no rule matched)
NCT02690350	An Open Study Assessing the Safety and Tolerability of U3-1784	Phase 1	terminated	Feb 24, 2016	Daiichi Sankyo	Program discontinued for business reasons (not safety).	Safety / toxicity
NCT01259024	The LC Bead Trial; Transarterial Chemoembolization of Hepatocellular Carcinoma (HCC)With…	N/A	terminated	Dec 13, 2010	Washington University School of Medicine	inability to obtain CMS approval	Other (stated, no rule matched)
NCT00459108	Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by…	Phase 2	terminated	Apr 11, 2007	National Cancer Institute (NCI)	Halted early for futility.	Efficacy / futility
NCT02149771	Combination Treatment for Advanced Liver Cancer	Phase 3	withdrawn	May 29, 2014	Shanghai Zhongshan Hospital	Insufficient funding	Funding
NCT02374489	A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or…	Phase 2	terminated	Feb 27, 2015	National Health Research Institutes, Taiwan	ROS1 in IHC and gene rearrangement result can not match。No tumor response。	Other (stated, no rule matched)
NCT02638909	Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal…	Phase 2	terminated	Dec 23, 2015	Criterium, Inc.	Lack of Enrollment	Enrollment / accrual
NCT01359007	FOLFIRINOX in Patients With Inoperable Pancreatic Cancer	Phase 2	terminated	May 24, 2011	University of Oklahoma	The principal investigator terminated the study due to inactivity and low enrollment	Investigator
NCT01710293	Intervention Protocol for Automated Point-of-Care Surveillance of Outpatient Delays in…(PACT CREATE 3)	N/A	withdrawn	Oct 19, 2012	VA Office of Research and Development	Unable to obtain data needed to run the RCT; project never began recruitment	Enrollment / accrual
NCT02105350	A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer	Phase 1	withdrawn	Apr 7, 2014	University Health Network, Toronto	Study was never initiated	Other (stated, no rule matched)
NCT02496832	A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With…	N/A	withdrawn	Jul 14, 2015	University Health Network, Toronto	Study was never initiated	Other (stated, no rule matched)
NCT03081039	A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant…	Phase 3	withdrawn	Mar 15, 2017	University of Louisville	Competing study	Other (stated, no rule matched)
NCT00878215	Clinical Application of Image-Guided Liver Surgery	Phase 2	terminated	Apr 8, 2009	Washington University School of Medicine	The image-guidance system became commercially available	Other (stated, no rule matched)
NCT01956864	Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer	Phase 1	withdrawn	Oct 8, 2013	Johns Hopkins University	PI transferred from Georgetown to Johns Hopkins University. No participants enrolled at either…	Enrollment / accrual
NCT01721174	Endoscopic Biliary Radiofrequency Ablation of Malignant Distal Common Bile Duct Strictures	N/A	terminated	Nov 5, 2012	Chinese University of Hong Kong	Poor recruitment	Enrollment / accrual
NCT02908165	Randomized Phase II Trial of Chemoembolization and Sorafenib	Phase 2	withdrawn	Sep 20, 2016	Yale University	A future study will be taking place using the same patient population.	Other (stated, no rule matched)
NCT00955721	A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With…	Phase 1 / Phase 2	terminated	Aug 10, 2009	University of Miami	Lack of Funding	Funding
NCT01012362	Study of Pazopanib and Ixabepilone in Patients With Solid Tumors	Phase 1	terminated	Nov 13, 2009	Masonic Cancer Center, University of Minnesota	PI left institution.	Investigator
NCT02406508	Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib…	Phase 2	withdrawn	Apr 2, 2015	Delcath Systems Inc.	No enrollment in the study	Enrollment / accrual
NCT02549755	11C-acetate for Treatment Response After Radiotherapy for HCC	Phase 2	terminated	Sep 15, 2015	Justin Sims	Poor enrollment	Enrollment / accrual
NCT00003530	Antineoplaston Therapy in Treating Patients With Primary Liver Cancer	Phase 2	terminated	Jan 27, 2003	Burzynski Research Institute	Slow accrual	Enrollment / accrual
NCT02958163	Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR)(HepSTAR)	Phase 2	terminated	Nov 8, 2016	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	lack of recruitment	Enrollment / accrual
NCT02106871	Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer(PCC)	Phase 1	withdrawn	Apr 8, 2014	The University of Texas Medical Branch, Galveston	Study did not get funded. Study never started	Funding
NCT02026362	Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients…(HCC DC CTL)	Phase 1 / Phase 2	suspended	Jan 3, 2014	HRYZ Biotech Co.	Interim analysis	Efficacy / futility
NCT02585687	Liver Perfusion MRI With Quantification of Tumoral Perfusion for Early Assessment of the…(ETAFIRM)	N/A	terminated	Oct 23, 2015	Hospices Civils de Lyon	problems with enrollment	Enrollment / accrual
NCT01489410	Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma	N/A	withdrawn	Dec 9, 2011	University of Minnesota	Insufficient staff	Other (stated, no rule matched)
NCT01668017	A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein…	Phase 1	terminated	Aug 17, 2012	Merck KGaA, Darmstadt, Germany	The sponsor decided not to conduct the expansion part of trial (part 2)	Sponsor / business decision

Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.

Data updated 23 days agoSource updated Feb 15, 2019source: clinicaltrials

Terminated, withdrawn and suspended studies

Stated reasons by category

Classification rules